On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Bell Potter is a big fan and highlights its established revenue stream from Illuccix and sees future product approvals (like Gozellix and Zircaix) as key drivers of potential upside. It also notes ...

Gozellix®, after radiolabeling with 68Ga, is indicated for PET Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory ...

These stocks could be top buys for investors looking to add to their portfolio. The post 5 top ASX 200 stocks that brokers rate as buys after the market selloff appeared first on The Motley Fool ...

Credit: Visby Medical. The approval was based on a clinical study that included 2203 females aged 14 years and older. The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s ...

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...